Thermo Fisher to Acquire Biolab for $120M | GenomeWeb

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific has signed a deal to acquire Australian analytical instruments and life science consumables provider Biolab for A$175 million (US $120 million).

Biolab is a division of publicly traded Australian firm Alesco Corp. and has annual revenues of around A$170 million. Thermo Fisher said that it expects to close the transaction on April 30, and that it will integrate the company in to its Laboratory Products and Services Segment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.